US FDA’s Coronavirus Workload Shifting Beyond Idea Stage
Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.
You may also be interested in...
Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.
Acting CDER Director Cavazzoni says it is ‘a very active time’ as many clinical trials for COVID-19-related products are expected to read out soon.
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.